News

Anda is currently the fourth-largest distributor of generic pharmaceuticals in the US. It delivers generic, brand, specialty, and over-the-counter pharmaceutical products from over 300 manufacturers to pharmacies. Under

The approval stipulates that patients whose tumors are EGFR or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with Keytruda. The approved

AVROBIO will use the proceeds from this financing to accelerate development of its clinical stage programs in Fabry disease and acute myeloid leukemia (AML), and to expand its

The companies plan to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens in order to enable

Allergan has received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of $53.39 for Teva Pharmaceutical

The companies struck a collaboration deal for the development and commercialization of ADXS-NEO. Under the deal, Amgen will pay Advaxis $40m upfront along with a $25m equity investment.

The US Food and Drug Administration granted the designation to LEE011 in combination with letrozole for treating hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced

The antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric patients. Following transfer of Y-mAbs' lead cell line to

Bamboo Therapeutics is engaged in the development of gene therapies for rare and devastating central nervous system and neuromuscular diseases In the first quarter of this year, Pfizer